Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer - Summary - MDSpire

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer

  • By

  • Marie Nour Karam

  • Joseph Hajj

  • Christopher H. Crane

  • Paul Ramia

  • Fady Geara

  • Nadim Hamadeh

  • Jacob G. Scott

  • Stephen Grobmyer

  • Rachael Almond

  • Eileen M. O’Reilly

  • Carla Hajj

  • June 8, 2026

  • 0 min

Share

Objective:

To examine the current literature on radiogenomics in pancreatic cancer and explore potential radiosensitizer drugs that may be paired with radiation therapy to target genetic effectors in pancreatic ductal adenocarcinoma (PDAC).

Key Findings:
  • Radiogenomics may improve personalized radiotherapy dosing.
  • PDAC is highly radioresistant, complicating treatment.
  • DDR inhibitors could enhance the effectiveness of radiotherapy in PDAC.
  • KRAS inhibitors present a novel opportunity for radiosensitization.
Interpretation:

Limitations:
  • Inconsistent findings across studies.
  • Inadequate PDAC-specific data.
  • Previous studies often underpowered and raised concerns over multiple comparisons.
Conclusion:

Original Source(s)

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer

  • by Marie Nour Karam, Joseph Hajj, Christopher H. Crane, Paul Ramia, Fady Geara, Nadim Hamadeh, Jacob G. Scott, Stephen Grobmyer, Rachael Almond, Eileen M. O’Reilly, Carla Hajj

  • June 8, 2026

Related Content

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

Case report: A challenging case of stage IVB mixed neuroendocrine-non-neuroendocrine neoplasm of the gallbladder treated with extended radical resection including portal vein reconstruction

NAT10 as a central node in cancer biology: integrating epitranscriptomic regulation, metabolic reprogramming, and immune modulation